Stem Cell-Based Therapy for Ischemic Heart Disease
Despite great advances in therapy over the past decades, ischemic heart disease (IHD) remains the leading cause of death worldwide because the decrease in mortality after acute myocardial infarction (AMI) leads to a longer life span in patients with chronic postinfarct heart failure (HF). There are...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2013-04-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.3727/096368912X655109 |
id |
doaj-867315b9033f41c19ce6e90fbe5cc95b |
---|---|
record_format |
Article |
spelling |
doaj-867315b9033f41c19ce6e90fbe5cc95b2020-11-25T03:33:01ZengSAGE PublishingCell Transplantation0963-68971555-38922013-04-012210.3727/096368912X655109Stem Cell-Based Therapy for Ischemic Heart DiseaseLien-Cheng Hsiao M.D.0Carolyn Carr D.Phil.1Kuan-Cheng Chang2Shinn-Zong Lin3Kieran Clarke4 Division of Cardiology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, ROCCardiac Metabolism Research Group, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK Division of Cardiology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, ROCGraduate Institute of Immunology, China Medical University, Taichung, Taiwan, ROCCardiac Metabolism Research Group, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UKDespite great advances in therapy over the past decades, ischemic heart disease (IHD) remains the leading cause of death worldwide because the decrease in mortality after acute myocardial infarction (AMI) leads to a longer life span in patients with chronic postinfarct heart failure (HF). There are no existing medical treatments that can cure chronic HF and the only currently available therapeutic option for end-stage HF is heart transplantation. However, transplantation is limited by the shortage of donor organs and patients require lifelong immunosuppression. In the past 10 years, stem cell-based cardiac therapy has been proposed as a promising approach for the treatment of IHD. There is a variety of potential stem cell types for cardiac repair and regeneration, including bone marrow cells (BMCs), resident cardiac stem cells (CSCs) and induced pluripotent stem cells (iPSCs). Stem cell-based therapy may comprise cell transplantation or cardiac tissue engineering (CTE), which might be an attractive alternative to solve the problems of low retention and poor survival of transplanted cells. This review focuses on the characteristics of stem cells from various sources and discusses the strategies of stem cell-based therapy for the treatment of IHD.https://doi.org/10.3727/096368912X655109 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lien-Cheng Hsiao M.D. Carolyn Carr D.Phil. Kuan-Cheng Chang Shinn-Zong Lin Kieran Clarke |
spellingShingle |
Lien-Cheng Hsiao M.D. Carolyn Carr D.Phil. Kuan-Cheng Chang Shinn-Zong Lin Kieran Clarke Stem Cell-Based Therapy for Ischemic Heart Disease Cell Transplantation |
author_facet |
Lien-Cheng Hsiao M.D. Carolyn Carr D.Phil. Kuan-Cheng Chang Shinn-Zong Lin Kieran Clarke |
author_sort |
Lien-Cheng Hsiao M.D. |
title |
Stem Cell-Based Therapy for Ischemic Heart Disease |
title_short |
Stem Cell-Based Therapy for Ischemic Heart Disease |
title_full |
Stem Cell-Based Therapy for Ischemic Heart Disease |
title_fullStr |
Stem Cell-Based Therapy for Ischemic Heart Disease |
title_full_unstemmed |
Stem Cell-Based Therapy for Ischemic Heart Disease |
title_sort |
stem cell-based therapy for ischemic heart disease |
publisher |
SAGE Publishing |
series |
Cell Transplantation |
issn |
0963-6897 1555-3892 |
publishDate |
2013-04-01 |
description |
Despite great advances in therapy over the past decades, ischemic heart disease (IHD) remains the leading cause of death worldwide because the decrease in mortality after acute myocardial infarction (AMI) leads to a longer life span in patients with chronic postinfarct heart failure (HF). There are no existing medical treatments that can cure chronic HF and the only currently available therapeutic option for end-stage HF is heart transplantation. However, transplantation is limited by the shortage of donor organs and patients require lifelong immunosuppression. In the past 10 years, stem cell-based cardiac therapy has been proposed as a promising approach for the treatment of IHD. There is a variety of potential stem cell types for cardiac repair and regeneration, including bone marrow cells (BMCs), resident cardiac stem cells (CSCs) and induced pluripotent stem cells (iPSCs). Stem cell-based therapy may comprise cell transplantation or cardiac tissue engineering (CTE), which might be an attractive alternative to solve the problems of low retention and poor survival of transplanted cells. This review focuses on the characteristics of stem cells from various sources and discusses the strategies of stem cell-based therapy for the treatment of IHD. |
url |
https://doi.org/10.3727/096368912X655109 |
work_keys_str_mv |
AT lienchenghsiaomd stemcellbasedtherapyforischemicheartdisease AT carolyncarrdphil stemcellbasedtherapyforischemicheartdisease AT kuanchengchang stemcellbasedtherapyforischemicheartdisease AT shinnzonglin stemcellbasedtherapyforischemicheartdisease AT kieranclarke stemcellbasedtherapyforischemicheartdisease |
_version_ |
1724565237611364352 |